The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine. 

After having invested in Morphic Therapeutic’s A and B rounds, AbbVie is pulling the trigger on an R&D deal.

The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago.

The FDA and the Department of Homeland Security are teaming up on securing medical devices from cyberattacks.

Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.

Novartis has tapped Foundation Medicine to develop companion diagnostic tests for its cancer treatment portfolio.

Eiger has given up on one of its rare disease candidates after a second negative trial, but a win for another drug has softened the blow.

The most advanced drug to get the chop is RG6125, an anti-cadherin 11 antibody that entered a phase 2 rheumatoid arthritis trial last year.